Boston, MA 03/21/2014 (wallstreetpr) – EntreMed Inc (NASDAQ:ENMD)’s beautiful pipeline continues to attract more investor interest. Traders are clearly buying into the prospects of the company’s drug candidates whose success is expected to be instant once they hit the market. In large volume trading session, shares of pharma jumped to a high of $2.09 Thursday, before settling at $2.05, up 12.64 percent. The shares opened at $1.80. The stock of the $55.43 million market capped company traded between $1.45 and $2.40 low and high respectively in the past one-year duration. With attractive pipeline, this stock can be a good portfolio add-on and investors are wise to keep a close eye here.
Neuralstem, Inc. (NYSEMKT:CUR) maintained its positive rally in the previous session, implying increasing interest in the stock among investors after positive finding came for its Phase 1 trial of a drug candidate. The company updated its study on NSI-566, which is stem-cell therapy. The concluded Phase 1 trial focused on the safety of the drug rather than efficiency. So then, it means the drug candidate will be subjected to more studies before it can see the light of the market. And this might take quite some time. However, that does not mean that the stock is not ripe for uptake. Shares jumped to a new 12-month high at $4.75, and settled at $4.61, up 12.17 percent by closing bell. Shares of Neuralstem, Inc. (NYSEMKT:CUR)opened the session at $4.07.
WSP Holdings Limited (ADR) (NYSE:WH) shares have had a nice uptrend since the company updated on the progress of its assets disposal. Shares were up 10.37 percent to $2.65 by closing bell on Thursday. The day saw heavy volume trading with share changing hands between $2.34 and $2.66. The shares which opened the last session at $2.40, traded between $1.61 and $3.10 in the past 12-month period. The announced disposal of assets will enable WSP Holdings Limited (ADR) (NYSE:WH) to avoid future losses stemming from the businesses, thus reducing cash burn.
